Profile of:

Gary Macfarlane

Gary Macfarlane is Dean for Interdisciplinary Research and Research Impact. He has also held the Chair in Epidemiology (Clinical) at The University of Aberdeen since 2005 and previously held the same post at The University of Manchester from 1999. He is an Honorary Consultant in the Department of Public Health in NHS Grampian. He trained in Statistics/ Computing Science and then Medicine at The University of Glasgow before undertaking his PhD at The University of Bristol. He worked at the Division of Epidemiology and Biostatistics at the European Institute of Oncology in Milan before leading a programme of chronic pain research at the Arthritis Research UK Epidemiology Unit at the University of Manchester. He leads the Epidemiology group at the University of Aberdeen which focusses its research in Rheumatic and Musculoskeletal Diseases (RMD). The RMD programme has programmes of research on: mechanisms of disease onset and outcome (observational epidemiology), identifying effective management for RMDs (Clinical trials and evidence synthesis), and designing optimal delivery of care (health services research). The clinical focus is on common complex conditions (including musculoskeletal pain and fatigue, fibromyalgia, and early osteoarthritis), inflammatory conditions, and rare diseases. He currently has 11 active grants (4 as Chief Investigator, 2 as Deputy Chief Investigator) worth £11.1m. The group runs the British Society of Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) and the BSR register in Psoriatic Arthritis (BSR-PsA). We are also part of the Arthritis Research UK/Medical Research Council Centre for Musculoskeletal Health and Work (of which Professor Macfarlane is Deputy Director). Professor Macfarlane is a Chartered Statistician of the Royal Statistical Society and a Fellow of the Faculty of Public Health Medicine.

Full name: Gary Macfarlane

Current country: United Kingdom

Membership level: Full

Type of membership: Member

Number of publications: 15

Inflammatory Bowel Disease Risk in Patients With Axial Spondyloarthritis Treated With Biologic Agents Determined Using the BSRBR-AS and a MetaAnalysis. (2023)

Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data. (2022)

The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis. (2021)

The role of metrology in axSpA: does it provide unique information in assessing patients and predicting outcome? Results from the BSRBR-AS registry. (2020)

Outcomes and treatment responses, including work productivity, among people with axial spondyloarthritis living in urban and rural areas: a mixed-methods study within a national register. (2020)

Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials? (2020)

Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS). (2020) (2020)

Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis. (2020)

Identifying Persons with Axial Spondyloarthritis At Risk of Poor Work Outcome: Results from the British Society for Rheumatology Biologics Register. (2019)

AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). (2019)

Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. (2018)

Relationship between diet and ankylosing spondylitis: A systematic review. (2018)

Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia: Results From a UK National Register. (2017)

Global prevalence of ankylosing spondylitis. (2014)